164 related articles for article (PubMed ID: 27587466)
1. Developing EZH2-Targeted Therapy for Lung Cancer.
Frankel AE; Liu X; Minna JD
Cancer Discov; 2016 Sep; 6(9):949-52. PubMed ID: 27587466
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.
Zhang H; Qi J; Reyes JM; Li L; Rao PK; Li F; Lin CY; Perry JA; Lawlor MA; Federation A; De Raedt T; Li YY; Liu Y; Duarte MA; Zhang Y; Herter-Sprie GS; Kikuchi E; Carretero J; Perou CM; Reibel JB; Paulk J; Bronson RT; Watanabe H; Brainson CF; Kim CF; Hammerman PS; Brown M; Cichowski K; Long H; Bradner JE; Wong KK
Cancer Discov; 2016 Sep; 6(9):1006-21. PubMed ID: 27312177
[TBL] [Abstract][Full Text] [Related]
3. A Potential Epigenetic Therapy for NSCLC.
Cancer Discov; 2015 Apr; 5(4):341. PubMed ID: 25724377
[TBL] [Abstract][Full Text] [Related]
4. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.
Grinshtein N; Rioseco CC; Marcellus R; Uehling D; Aman A; Lun X; Muto O; Podmore L; Lever J; Shen Y; Blough MD; Cairncross GJ; Robbins SM; Jones SJ; Marra MA; Al-Awar R; Senger DL; Kaplan DR
Oncotarget; 2016 Sep; 7(37):59360-59376. PubMed ID: 27449082
[TBL] [Abstract][Full Text] [Related]
5. Enhancer of zeste homolog 2 (EZH2) inhibitors.
Gulati N; Béguelin W; Giulino-Roth L
Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
[TBL] [Abstract][Full Text] [Related]
6. Anticancer drugs: All roads lead to EZH2 inhibition.
Villanueva MT
Nat Rev Drug Discov; 2017 Mar; 16(4):239. PubMed ID: 28356595
[No Abstract] [Full Text] [Related]
7. BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.
Genta S; Pirosa MC; Stathis A
Curr Oncol Rep; 2019 Feb; 21(2):13. PubMed ID: 30715616
[TBL] [Abstract][Full Text] [Related]
8. Discovery, design, and synthesis of indole-based EZH2 inhibitors.
Gehling VS; Vaswani RG; Nasveschuk CG; Duplessis M; Iyer P; Balasubramanian S; Zhao F; Good AC; Campbell R; Lee C; Dakin LA; Cook AS; Gagnon A; Harmange JC; Audia JE; Cummings RT; Normant E; Trojer P; Albrecht BK
Bioorg Med Chem Lett; 2015 Sep; 25(17):3644-9. PubMed ID: 26189078
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of chemokine CCL2 represses macrophage infiltration to potentiate tumor development in small cell lung cancer.
Zheng Y; Wang Z; Wei S; Liu Z; Chen G
Cancer Lett; 2021 Feb; 499():148-163. PubMed ID: 33253790
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor and anti-metastasis activities of honey bee larvae powder by suppressing the expression of EZH2.
Kageyama M; Li K; Sun S; Xing G; Gao R; Lei Z; Zhang Z
Biomed Pharmacother; 2018 Sep; 105():690-696. PubMed ID: 29906747
[TBL] [Abstract][Full Text] [Related]
11. Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program.
Hirukawa A; Smith HW; Zuo D; Dufour CR; Savage P; Bertos N; Johnson RM; Bui T; Bourque G; Basik M; Giguère V; Park M; Muller WJ
Nat Commun; 2018 Jun; 9(1):2547. PubMed ID: 29959321
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein.
Tripathi BK; Anderman MF; Bhargava D; Boccuzzi L; Qian X; Wang D; Durkin ME; Papageorge AG; de Miguel FJ; Politi K; Walters KJ; Doroshow JH; Lowy DR
Nat Commun; 2021 Dec; 12(1):6941. PubMed ID: 34862367
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
14. Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.
Kung PP; Rui E; Bergqvist S; Bingham P; Braganza J; Collins M; Cui M; Diehl W; Dinh D; Fan C; Fantin VR; Gukasyan HJ; Hu W; Huang B; Kephart S; Krivacic C; Kumpf RA; Li G; Maegley KA; McAlpine I; Nguyen L; Ninkovic S; Ornelas M; Ryskin M; Scales S; Sutton S; Tatlock J; Verhelle D; Wang F; Wells P; Wythes M; Yamazaki S; Yip B; Yu X; Zehnder L; Zhang WG; Rollins RA; Edwards M
J Med Chem; 2016 Sep; 59(18):8306-25. PubMed ID: 27512831
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer.
Deblois G; Tonekaboni SAM; Grillo G; Martinez C; Kao YI; Tai F; Ettayebi I; Fortier AM; Savage P; Fedor AN; Liu X; Guilhamon P; Lima-Fernandes E; Murison A; Kuasne H; Ba-Alawi W; Cescon DW; Arrowsmith CH; De Carvalho DD; Haibe-Kains B; Locasale JW; Park M; Lupien M
Cancer Discov; 2020 Sep; 10(9):1312-1329. PubMed ID: 32546577
[TBL] [Abstract][Full Text] [Related]
16. Differentiation therapy: a promising strategy for cancer treatment.
Yan M; Liu Q
Chin J Cancer; 2016 Jan; 35():3. PubMed ID: 26739838
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of benzomorpholine derivatives as novel EZH2 inhibitors for anti-non-small cell lung cancer activity.
Feng Q; He H; Gao T; Zhang Q; Liu Z; Tao X; Zhu Y; Zhang L; Yu L
Mol Divers; 2019 Aug; 23(3):681-696. PubMed ID: 30612258
[TBL] [Abstract][Full Text] [Related]
18. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer.
Italiano A
Pharmacol Ther; 2016 Sep; 165():26-31. PubMed ID: 27179746
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
[TBL] [Abstract][Full Text] [Related]
20. Targeting epigenetics in sarcomas through EZH2 inhibition.
Italiano A
J Hematol Oncol; 2020 Apr; 13(1):33. PubMed ID: 32264965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
